Dr. Michael Soulen, MD
Claim this profileUniversity of Pennsylvania
Studies Neuroendocrine Tumors
Studies Liver Cancer
7 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Michael Soulen, MD is currently running
Noninvasive SHAPE
for Portal Hypertension
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE (subharmonic aided pressure estimation) procedures using different ultrasound contrast agents (Definity \[Lantheus Medical Imaging, N Bilerica, MA, USA\] and Sonazoid \[GE Healthcare, Oslo, Norway\] in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare, Waukesha, WI, USA) and determine the reproducibility of the SHAPE algorithm. Cohort 2: Patients identified as having clinically significant portal hypertension (CSPH) will be monitored by SHAPE with Sonazoid for the duration of this project (18-24 months on average). These subjects will have follow-up ultrasound scans every 6 ± 2 months to check for hepatocellular carcinoma (HCC) (using the Barcelona-Liver Cancer staging system) as well as ascites and at those times a repeat SHAPE examination will be performed. Liver stiffness values will be measured with elastography as well. This cohort will examine if serial SHAPE can accurately predict development of ascites and other liver related events in patients with compensated cirrhosis undergoing routine HCC surveillance in a multi-center setting. Cohort 3: Subjects newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE and results compared to elastography measurements of liver stiffness with standard assessments (e.g., serum liver function tests and measurement of spleen size as well as platelet count). This cohort will establish if SHAPE can be used to monitor treatment response in patients identified with portal hypertension. Cohort 4: Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices relative to the Baveno VI and the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index will undergo a SHAPE examination. This cohort will compare the predictive ability of SHAPE for allocating patients with compensated advanced chronic liver disease to screening of varices compared to the current standard of care.
Recruiting4 awards Phase 39 criteria
CapTem + Y90
for Neuroendocrine Cancer
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.
Recruiting1 award Phase 2
More about Michael Soulen, MD
Clinical Trial Related3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Michael Soulen, MD has experience with
- Capecitabine
- SIR-Spheres
- Temozolomide
- Tirapazamine
- Transarterial Embolization (TAE)
- Capecitabine Oral Product
Breakdown of trials Michael Soulen, MD has run
Neuroendocrine Tumors
Liver Cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Soulen, MD specialize in?
Michael Soulen, MD focuses on Neuroendocrine Tumors and Liver Cancer. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are undergoing treatment.
Is Michael Soulen, MD currently recruiting for clinical trials?
Yes, Michael Soulen, MD is currently recruiting for 5 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Michael Soulen, MD has studied deeply?
Yes, Michael Soulen, MD has studied treatments such as Capecitabine, SIR-Spheres, Temozolomide.
What is the best way to schedule an appointment with Michael Soulen, MD?
Apply for one of the trials that Michael Soulen, MD is conducting.
What is the office address of Michael Soulen, MD?
The office of Michael Soulen, MD is located at: University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the University of Pennsylvania.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.